Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

References

• Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:1–19. doi:10.1186/s13023-015-0310-1
   PubMed Web of Science ®Google Scholar
• de Correia AC, Silva PCB, da Silva BA. Malignant hyperthermia: clinical and molecular aspects. Rev Bras Anestesiol. 2012;62:820–837. doi:10.1016/S0034-7094(12)70182-4
   PubMed Web of Science ®Google Scholar
• Broman M, Islander G, Müller CR. Malignant hyperthermia, a Scandinavian update. Acta Anaesthesiol Scand. 2015;59:951–961. doi:10.1111/aas.12541
   PubMed Web of Science ®Google Scholar
• Julien Marsollier F, Roux-Buisson N, Dalmas AF, Bruneau B, Dahmani S. Management of malignant hyperthermia in France: current organisation. Anaesthes Crit Care Pain Med. 2019;38:535. doi:10.1016/j.accpm.2019.02.008
   PubMed Web of Science ®Google Scholar
• Litman RS, Smith VI, Larach MG, et al. Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth Analg. 2019;128:652–659. doi:10.1213/ANE.0000000000004039
   PubMed Web of Science ®Google Scholar
• Rüffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126:120–130. doi:10.1016/j.bja.2020.09.029
   PubMed Web of Science ®Google Scholar
• Jones PM, Allen BN, Cherry RA, et al. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Can J Anesth. 2019;66:161–181. doi:10.1007/s12630-018-1250-8
   PubMed Web of Science ®Google Scholar
• Ibarra Moreno CA, Hu S, Kraeva N, et al. An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology. 2019;131:983–991. doi:10.1097/ALN.0000000000002813
   PubMed Web of Science ®Google Scholar
• Lu Z, Rosenberg H, Li G. Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin. J Clin Anesth. 2017;39:10–14. doi:10.1016/j.jclinane.2017.03.016
   PubMed Web of Science ®Google Scholar
• Li Z, Liu K, Guo X. Dantrolene available in china for malignant hyperthermia treatment. Anesthesiology. 2022;136:515–516. doi:10.1097/ALN.0000000000003998
   Web of Science ®Google Scholar
• Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168–180. doi:10.1097/ALN.0000000000001878
   PubMed Web of Science ®Google Scholar
• Miller DM, Daly C, Aboelsaod EM, et al. Genetic epidemiology of malignant hyperthermia in the UK. Br J Anaesth. 2018;121:944–952. doi:10.1016/j.bja.2018.06.028
   PubMed Web of Science ®Google Scholar
• Wang YL, Luo AL, Tan G, Cui XL, Guo XY. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007. Chin Med J. 2010;123:1241–1245.
   PubMed Web of Science ®Google Scholar
• Belani KG, Cao C, Daugherty D, et al. Malignant hyperthermia status in China. Anesth Analg. 2016;122:574–577. doi:10.1213/ANE.0000000000001043
   Google Scholar
• Hu X, Li X, Lü Y, Tang J, Li HR, Tang M. Effect of WeChat consultation group on residents staying at home in Sichuan and Chongqing regions during the Coronavirus Disease 2019 (COVID-19) outbreak in China: a cross-sectional study. BMC Public Health. 2020;20:1–9. doi:10.1186/s12889-020-09951-4
   PubMed Web of Science ®Google Scholar
• Montag C, Becker B, Gan C. The multipurpose application WeChat: a review on recent research. Front Psychol. 2018;9:1–8. doi:10.3389/fpsyg.2018.02247
   PubMed Web of Science ®Google Scholar
• Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–779. doi:10.1097/00000542-199404000-00008
   PubMed Web of Science ®Google Scholar
• Bendahan D, Guis NM, Kozak-Ribbens G, et al. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand. 2004;44:1019–1027. doi:10.1111/j.0001-5172.2004.00461.x
   Web of Science ®Google Scholar
• Fang Y, Wu JB, Ding ZN. Clinical analysis of malignant hyperthermia reported cases from 1970 to 2017 in China. Jiangsu Med. 2018;44:843–846.
   Google Scholar
• Pinyavat T, Henry Rosenberg BH, Lang CAW, Sheila Riazi JE, Brady LS, Sun GL. Accuracy of malignant hyperthermia diagnoses in hospital discharge records. Anesthesiology. 2015;122:55–63. doi:10.1097/ALN.0000000000000467
   PubMed Web of Science ®Google Scholar
• Rutkowsky JM, Knotts TA, Allen PD, Pessah IN, Ramsey JJ. Sex-specific alterations in whole body energetics and voluntary activity in heterozygous R163C malignant hyperthermia-susceptible mice. FASEB J. 2020;34:8721–8733. doi:10.1096/fj.202000403
   PubMed Web of Science ®Google Scholar
• Klingler W, Heiderich S, Girard T, et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis. 2014;9. doi:10.1186/1750-1172-9-8.
   PubMed Web of Science ®Google Scholar
• Horstick EJ, Linsley JW, Dowling JJ, et al. Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy. Nat Commun. 2013;4. doi:10.1038/ncomms2952
   PubMed Web of Science ®Google Scholar
• Polster A, Nelson BR, Olson EN, Beam KG. Stac3 has a direct role in skeletal muscle-type excitation-contraction coupling that is disrupted by a myopathy-causing mutation. Proc Natl Acad Sci U S A. 2016;113:10986–10991. doi:10.1073/pnas.1612441113
   PubMed Web of Science ®Google Scholar
• Yang L, Tautz T, Zhang S, Fomina A, Liu H. The current status of malignant hyperthermia. J Biomed Res. 2020;34:75–85. doi:10.7555/JBR.33.20180089
   Web of Science ®Google Scholar
• Vanden AF, Lotteau S, Ducreux S, et al. TRPV1 variants impair intracellular Ca 2+ signaling and may confer susceptibility to malignant hyperthermia. Genet Med. 2019;21:441–450. doi:10.1038/s41436-018-0066-9
   PubMed Web of Science ®Google Scholar
• Ho PT, Carvalho B, Sun EC, Macario A, Riley ET. Cost-benefit analysis of maintaining a fully stocked malignant hyperthermia cart versus an initial dantrolene treatment dose for maternity units. Anesthesiology. 2018;129:249–259. doi:10.1097/ALN.0000000000002231
   PubMed Web of Science ®Google Scholar
• Guglielminotti J, Rosenberg H, Li G. Prevalence of malignant hyperthermia diagnosis in obstetric patients in the United States, 2003 to 2014. BMC Anesthesiol. 2020;20. doi:10.1186/s12871-020-0934-0
   PubMed Web of Science ®Google Scholar
• Changsheng H, Ahn Wonsik GQ, Guo Q. Current state of malignant hyperthermia in China mainland: a less optimistic reality. Paediatr Anaesth. 2012;22:503–504. doi:10.1111/j.1460-9592.2011.03774.x
   PubMed Web of Science ®Google Scholar
• Wang X, Tao J, Zhu Q, et al. Depression and anxiety symptoms to COVID-19 outbreak among the public, medical staff and patients during the initial phase of the pandemic: an online questionnaire survey by a WeChat Mini Program. BMJ Open. 2021;11:115.
   Web of Science ®Google Scholar
• Ding Y, Lu X, Xie Z, Jiang T, Song C, Wang Z. Evaluation of a novel wechat applet for image-based dietary assessment among pregnant women in China. Nutrients. 2021;13:3158. doi:10.3390/nu13093158
   PubMed Web of Science ®Google Scholar
• Li Q, Deng X, Yan J, et al. Neonatal severe hyperbilirubinemia online registry in Jiangsu Province: protocol for a multicentre, prospective, open, observational cohort study. BMJ Open. 2021;11:1–7.
   Google Scholar